Day One Bio Day One Bio

Our treatments have the potential to save lives, our pipeline aims to protect futures and our commitment aspires to elevate what can be achieved in oncology.

Product Candidate
Therapeutic Area
  • Pre-CN
  • Ph 1
  • Ph 2
  • Ph 3/Reg
  • Approved
Tovorafenib Type II RAF inhibitor

OJEMDA™ brand name
in US1


Therapeutic Area: BRAF-altered
Relapsed pLGG

Progress: Phase 2

Clinical Trial: FIREFLY-1 (pivotal Phase 2)

  • PH2
FIREFLY-1 (pivotal Phase 2)

Therapeutic Area: Front-line
RAF-altered pLGG

Progress: Phase 3

Clinical Trial: FIREFLY-2 (pivotal Phase 3)

  • PH3
FIREFLY-2 (pivotal Phase 3)
Pimasertib MEK 1/2 inhibitor

Therapeutic Area: MAPK-altered
solid tumors
(combination with tovorafenib)

Progress: Phase 1

Clinical Trial: FIRELIGHT-1††

  • PH1
VRK1 Program VRK1 inhibitor

Therapeutic Area: Pediatric and adult cancers

Progress: Pre-Clinical

Clinical Trial:

  • PreCN

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.

1 OJEMDA has received accelerated approval by the U.S. Food and Drug Administration. 
 Pimasertib Phase 1 dose escalation and expansion trial previously completed. 
†† Includes patients ≥12 years of age. 
§ Research collaboration and license agreement with Sprint Bioscience for exclusive worldwide rights to a research-stage program targeting VRK1. 

You are now leaving the Day One Biopharmaceuticals Corporate Website

You will now be redirected to the requested website. Please confirm that you want to proceed.